By Nadia ElKaissi, CHTM
When the U.S. Food and Drug Administration (FDA) updates its playbook, the healthcare world pays attention. Its recent introduction of 19 new medical device categories may sound technical, but the implications are wide-reaching. These new classifications aim to reflect modern technologies more accurately – everything from connected wearables to AI-driven diagnostic software. For hospitals, though, these shifts can have real consequences for how devices are evaluated for risk and how HTM and OIT teams manage controls.
WHY THE FDA UPDATED CATEGORIES
Medical devices are no longer just scalpels and scanners. Today’s devices are often hybrids of hardware, software and connectivity. For instance, a defibrillator is no longer just a box with paddles; it’s a network-enabled tool that records patient data, integrates with electronic health records (EHRs) and can even be updated via software updates. By introducing 19 new categories, the FDA is drawing a sharper distinction that reflects real-world device complexity and risk. Instead of trying to fit modern tools into outdated buckets, the agency is giving hospitals, manufacturers and regulators clearer frameworks for oversight. This makes risk assessments more consistent, device approval more transparent and smoother development for manufacturers.
RISK ASSESSMENT RIPPLE
Risk assessment is the backbone of hospital decision-making around new technology. Before adopting any device – whether it’s a bedside monitor or a life-saving infusion pump – hospitals evaluate how failure, misuse, or compromise could effect patients. The new FDA categories will shift those evaluations in important ways.
1. Category=Risk Signal: If a device, such as a defibrillator or infusion pump, is classified in a higher-risk category, hospitals must implement stricter validation, documentation and monitoring procedures. Reclassification isn’t just a bureaucratic detail – it directly affects how much oversight HTM, OIT and clinical teams must apply.
2. Software as a Device: Many modern defibrillators and infusion pumps are controlled by embedded software and often connect to hospital networks. If the FDA explicitly defines these as “software-containing devices,” hospitals must now treat not only the hardware but also the code inside as part of the risk assessment.
3. Operational Impact: A defibrillator failure could mean immediate harm. While an infusion pump delivering the wrong dosage could cause long-term damage. Their placement in higher-risk categories formalizes what hospitals already know instinctively: the stakes are too high for minimal impact.
For hospitals, the immediate result of these new FDA categories may be more work upfront – new training, revised policies, and tighter HTM and IT oversight. Defibrillators, infusion pumps and similar devices will demand more stringent controls, and IT teams may find themselves, rewriting procedures that once seemed adequate.
But in the bigger picture, this is an opportunity. Hospitals can move toward risk-based IT control models where the rigor of oversight matches the device’s clinical importance. Instead of one-size-fits-all policies, high-risk devices like infusion pumps, and defibrillators will get the protection they deserve, while lower-risk devices can be managed more flexibly.
Still, it’s important to recognize that while FDA categories are a useful starting point, they are not the whole story. Categories offer a framework, but true risk evaluation must also factor in variables such as device connectivity, multi-factor authentication, vendor support and even the threat landscape at a given moment. A reclassified device might look high-risk on paper but have strong built-in safeguards; another might sit in a lower category yet pose a bigger cyber risk if poorly maintained.
In other words, the new FDA categories highlight crucial aspects of device safety, but hospitals must layer that guidance with their own clinical, operational and cybersecurity insights. Only then can they build a complete resilient picture of risk – one that goes beyond mere labels and reclassifications.
